ZYMFENTRA
Scope
Date
~
-
Bio & PharmaCelltrion's Zymfentra gets 90% distribution channel in US
South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...
Oct 30, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion's Zymfentra joins US insurance-covered drug lists
South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...
Aug 06, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
May 23, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand
